GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » 3-Year EPS without NRI Growth Rate

Innovative Pharmaceutical Biotech (HKSE:00399) 3-Year EPS without NRI Growth Rate : -15.20% (As of Sep. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Innovative Pharmaceutical Biotech 3-Year EPS without NRI Growth Rate?

Innovative Pharmaceutical Biotech's EPS without NRI for the six months ended in Sep. 2023 was HK$-0.21.

During the past 3 years, the average EPS without NRI Growth Rate was -15.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -18.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Innovative Pharmaceutical Biotech was 65.00% per year. The lowest was -22.70% per year. And the median was -15.05% per year.


Competitive Comparison of Innovative Pharmaceutical Biotech's 3-Year EPS without NRI Growth Rate

For the Household & Personal Products subindustry, Innovative Pharmaceutical Biotech's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovative Pharmaceutical Biotech's 3-Year EPS without NRI Growth Rate Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Innovative Pharmaceutical Biotech's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Innovative Pharmaceutical Biotech's 3-Year EPS without NRI Growth Rate falls into.



Innovative Pharmaceutical Biotech 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Innovative Pharmaceutical Biotech  (HKSE:00399) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Innovative Pharmaceutical Biotech 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovative Pharmaceutical Biotech (HKSE:00399) Business Description

Traded in Other Exchanges
N/A
Address
168-200 Connaught Road Central, Unit No. 2111, 21st Floor, Sheung Wan, West Tower Shun Tak Centre, Hong Kong, HKG
Innovative Pharmaceutical Biotech Ltd is focused on developing an insulin product that could be administered orally. It has two primary segments of business: the research and development of pharmaceutical products and the trading of beauty products. It generates maximum revenue from trading in the beauty products segment.
Executives
Mao Yumin 2101 Beneficial owner
Extrawell Pharmaceutical Holdings Limited
Chau Yiu Ting 2101 Beneficial owner
Mao Yumin 2101 Beneficial owner
Chau Yiu Ting 2101 Beneficial owner

Innovative Pharmaceutical Biotech (HKSE:00399) Headlines

No Headlines